# Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

> **NCT06850454** · PHASE3 · RECRUITING · sponsor: **Mahidol University** · enrollment: 140 (estimated)

## Conditions studied

- Chemotherapy Induced Nausea and Vomiting

## Interventions

- **DRUG:** olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06850454
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2026-01-10
- **Final completion:** 2026-01-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850454, "Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06850454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*